Structural requirements for cationic lipid mediated phosphorothioate oligonucleotides delivery to cells in culture

被引:45
作者
Bennett, CF
Mirejovsky, D
Crooke, RM
Tsai, YJ
Felgner, J
Sridhar, CN
Wheeler, CJ
Felgner, PL
机构
[1] ISIS Pharmaceut, Carlsbad, CA 92008 USA
[2] VICAL Inc, San Diego, CA 92121 USA
关键词
cationic liposome; antisense oligonucleotide; drug delivery; ICAM-1; fusion;
D O I
10.3109/10611869808995870
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
A series of 2,3-dialkyloxypropyl quaternary ammonium lipids containing hydroxyalkyl chains on the quaternary amine were synthesized, formulated with dioleoylphosphatidylethanolamine (DOPE) and assayed for their ability to enhance the activity of an intercellular adhesion molecule I (ICAM-1) antisense oligonucleotide, ISIS 1570. Cationic liposomes prepared with hydroxyethyl, hydroxypropyl and hydroxybutyl substituted cationic lipid all enhanced the activity of the ICAM-1 antisense oligonucleotide. Cationic lipids containing hydroxypentyl quaternary amines only marginally enhanced the activity of ISIS 1570. Hydroxyethyl cationic lipids synthesized with dimyristyl (C-14:0) and dioleyl (C-18:1) alkyl chains were equally effective. Activity of cationic lipids containing saturated alkyl groups decreased as the chain length increased, i.e. the dimyristyl (C-14:0) was more effective than dipalmityl (C-16:0) lipid, which was more effective than distearyl (C-18:0). The phase transition temperature of cationic lipids containing saturated aliphatic chains was 56 degrees C for the distearyl lipid, 42 degrees C for the dipalmityl lipid and 24 degrees C for the dimyristyl lipid, Cationic lipids with dioleyl alkyl chains required DOPE for activity, with optimal activity occurring at 50 mole%. In contrast, a dimyristyl containing cationic lipid did not require DOPE to enhance the activity of ISIS 1570. Formulation with different phosphatidylethanolamine derivatives, revealed that optimal activity was obtained with DOPE. These studies demonstrate that several cationic lipid species enhance the activity of phosphorothioate antisense oligonucleotides and provide further information on the mechanism by which cationic lipids enhance the activity of phosphorothioate oligodeoxynucleotides.
引用
收藏
页码:149 / 162
页数:14
相关论文
共 52 条
  • [31] Fate of cationic liposomes and their complex with oligonucleotide in vivo
    Litzinger, DC
    Brown, JM
    Wala, I
    Kaufman, SA
    Van, GY
    Farrell, CL
    Collins, D
    [J]. BIOCHIMICA ET BIOPHYSICA ACTA-BIOMEMBRANES, 1996, 1281 (02): : 139 - 149
  • [32] CHARACTERIZATION OF OLIGONUCLEOTIDE TRANSPORT INTO LIVING CELLS
    LOKE, SL
    STEIN, CA
    ZHANG, XH
    MORI, K
    NAKANISHI, M
    SUBASINGHE, C
    COHEN, JS
    NECKERS, LM
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1989, 86 (10) : 3474 - 3478
  • [33] ENHANCED METASTATIC ABILITY OF TNF-ALPHA-TREATED MALIGNANT-MELANOMA CELLS IS REDUCED BY INTERCELLULAR-ADHESION MOLECULE-1 (ICAM-1, CD54) ANTISENSE OLIGONUCLEOTIDES
    MIELE, ME
    BENNETT, CF
    MILLER, BE
    WELCH, DR
    [J]. EXPERIMENTAL CELL RESEARCH, 1994, 214 (01) : 231 - 241
  • [34] CURRENT CONCEPTS IN ANTISENSE DRUG DESIGN
    MILLIGAN, JF
    MATTEUCCI, MD
    MARTIN, JC
    [J]. JOURNAL OF MEDICINAL CHEMISTRY, 1993, 36 (14) : 1923 - 1937
  • [35] Antitumor activity of a phosphorothioate antisense oligodeoxynucleotide targeted against C-raf kinase
    Monia, BP
    Johnston, JF
    Geiger, T
    Muller, M
    Fabbro, D
    [J]. NATURE MEDICINE, 1996, 2 (06) : 668 - 675
  • [36] Nuclease resistance and antisense activity of modified oligonucleotides targeted to Ha-ras
    Monia, BP
    Johnston, JF
    Sasmor, H
    Cummins, LL
    [J]. JOURNAL OF BIOLOGICAL CHEMISTRY, 1996, 271 (24) : 14533 - 14540
  • [37] MONIA BP, 1992, J BIOL CHEM, V267, P19954
  • [38] MONIA BP, 1993, J BIOL CHEM, V268, P14514
  • [39] SITE-SPECIFIC GENE-EXPRESSION INVIVO BY DIRECT GENE-TRANSFER INTO THE ARTERIAL-WALL
    NABEL, EG
    PLAUTZ, G
    NABEL, GJ
    [J]. SCIENCE, 1990, 249 (4974) : 1285 - 1288
  • [40] PERLAKY L, 1993, ANTI-CANCER DRUG DES, V8, P3